In focus · trending topic

proqr therapeutics

21 stories · following the connections

ProQR Announces Conference Presentations for Axiomer® RNA Editing Technology and QR-313 for DEB

By Nasdaq OMXApr 30, 2018, 11:00 AM UTC

ProQR to Present at Two Upcoming Conferences

By Nasdaq OMXApr 3, 2018, 11:00 AM UTC

ProQR to Present at Upcoming Investor Conference

By Nasdaq OMXMar 5, 2018, 12:01 PM UTC

Foundation Fighting Blindness will provide up to $7.5 million in funding to develop ProQR’s candidate QR-421a for Usher syndrome type 2A

By Nasdaq OMXFeb 12, 2018, 12:01 PM UTC

ProQR to Present at Upcoming Scientific Meeting and Investor Conference

By Nasdaq OMXFeb 6, 2018, 12:00 PM UTC

ProQR and Galapagos Announce Research Collaboration on Fibrosis Targets Using ProQR’s Axiomer® technology

By Nasdaq OMXJan 8, 2018, 12:01 PM UTC

ProQR Announces Extraordinary General Meeting of Shareholders

By Nasdaq OMXDec 27, 2017, 12:01 PM UTC

ProQR Receives Orphan Drug Designation from EMA for Drug Candidate QR-313 for Dystrophic Epidermolysis Bullosa

By Nasdaq OMXNov 29, 2017, 12:00 PM UTC